JPMorgan lowered the firm’s price target on BioNTech (BNTX) to $124 from $125 and keeps a Neutral rating on the shares. The firm updated estimates following Pfizer’s Comirnaty results and vaccine script trends for Comirnaty, Spikevax, and mResvia.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- BioNTech’s Q3 2024: Strong Revenue and Oncology Progress
- BioNTech SE Reports Strong Revenue Growth Amid Rising R&D Costs
- Options Volatility and Implied Earnings Moves Today, November 04, 2024
- BioNTech lowers FY24 CapEx view to EUR 300M-EUR 400M
- BioNTech reports Q3 EPS EUR 0.81 vs. EUR 0.66 last year